Overview

A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients.

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A study to determine the ability of different doses of PF-610,355 to open the airways in asthmatic patients by comparison with placebo and a marketed drug that also opens the airways in asthmatic patients.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Salmeterol Xinafoate